Proactive Investors - Run By Investors For Investors

Avalon GloboCare CEO David Jin to unveil exosome commercialization plan at China confab

Jin on Saturday will lead a session on 'Application of Stem Cell Exosomes' at the Second International Aesthetic Industry Conference in Chengdu, China
cell
Exosomes are powerful messengers released by cells into urine and saliva, and can help fight cancer

Avalon GloboCare (NASDAQ:AVCO) announced Thursday that CEO David Jin will unveil the launch of the company’s new commercialization plan for its exosome products at a conference in China.

Dr Jin on Saturday will lead a session on "Application of Stem Cell Exosomes" at the Second International Aesthetic Industry Conference in Chengdu.

Exosomes are powerful messengers released by cells into biofluids like plasma/serum, urine, and saliva.

Avalon says exosomes can help fight the progression of certain cancers and act as biomarkers to detect tumors.

At the conference, the Freehold, New Jersey-based company will provide a series of skincare and wound-healing products using Avalon's clinical-grade tissue-specific exosomes as additives.

"Avalon GloboCare is dedicated to assembling and integrating the premier scientific, clinical, and regulatory resources from around the world, in order to accelerate innovative and transformative cellular and exosome-based technologies, as well as their clinical applications," Jin said in a statement. "We are honored to lead a panel with international experts to discuss this evolving ecosystem, as well as showcasing our exosome product commercialization plan."

READ: Avalon GloboCare's stock soars after positive study on first saliva-based biomarker as a diagnostic for oral cancer

In addition, Yu Zhou, the co-CEO of Avalon's subsidiary, GenExosome Technologies, will provide the conference keynote address.  

GenExosome Technologies developed the proprietary exosome isolation systems to promote implementation of exosome biotechnology in "liquid biopsies" and provide innovative exosome products for clinical diagnosis and treatment, Avalon said.

Yu Zhou's keynote presentation is titled "Application of Exosome Technology in Aesthetic Industry: Isolation, Quality Control, and Exosomic Analysis."  

Avalon specializes in developing cell-based technologies but is also involved in the management of stem cell banks and clinical laboratories. It also develops proprietary diagnostic and therapeutic products leveraging exosome technology and markets proprietary exosome isolation systems and related products to hospitals.

The company’s stock recently traded up 0.87% to $2.32 a share.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full AVCO profile View Profile

Avalon GloboCare Corp Timeline

Related Articles

cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
patch
May 19 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use